Laboratory Assessment of Postmenopausal Osteoporosis

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 611-628

  Garnero, Patrick ^a,c   Delmas, Pierre D ^b,c  

^a Molecular Markers   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882506589     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50038-8     Document Type: Chapter

References (146)

1. World Health Organisation Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843 1994, WHO, Geneva.
2. Cooper C., Atkinson E.J., O'Falon W.M., Melton L.J. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester Minnesota, 1985-1989. J. Bone Miner. Res. 1992, 7:221-227.
3. Gallagher J.C., Kinyamu H.K., Fowler S.E., Dawson-Hughes B., Dalsky G.P., Sherman S.S. Calciotropic hormones and bone markers in the elderly. J. Bone Miner. Res. 1998, 13:475-482.
4. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 1997, 337:670-676.
5. Riggs B.L., Wahner H.W., Melton L.J., Richelson L.S., Judd H.L., Offord K.P. Rates of bone loss in the appendicular and axial skeletons of women: evidence of substantial bone loss prior to menopause. J. Clin. Invest. 1985, 77:1487-1491.
6. Riggs B.L., Wahner H.W., Dunn W.L., Seenan, Offord K.P., Dunn W.L., Mazen R.B., Johnson K.A., Melton L.J. Changes in bone mineral density of the proximal femur and spine with aging. J. Clin. Invest. 1982, 70:716-723.
7. Arlot M.E., Somay-Rendu E., Gamero P., Vey-Marty B., Delmas P.D. Pre and postmenopausal bone loss evaluated by DXA at different skeletal sites in healthy women: The OFELY cohort. J. Bone Miner. Res. 1997, 12:683-690.
8. Pouilles J.M., Tremollieres F., Ribot C. The effects of menopause on longitudinal bone loss from the spine. Calcif. Tissue Int. 1993, 52:340-343.
9. Hui S.L., Slemenda W., Johnston C.C., Appledorn C.R. Effects of age and menopause on vertebral bone density. Bone Miner. 1987, 2:141-146.
10. Ribot C., Tremollières F., Pouilles J.M., Louvet J.P., Guirand R. Influence of the menopause and aging on spinal density in French women. Bone Miner. 1988, 5:89-97.
11. Heldlund L.R., Gallagher J.C. The effect of age and menopause on bone mineral density of the proximal femur. J. Bone Miner. Res. 1989, 4:639-641.
12. Nordin B.E.C., Need A.G., Chatterton B.E., Horowitz M., Morris H.A. The relative contributions of age and years since menopause to postmenopausal bone loss. J. Clin. Endocrinol. Metab. 1989, 70:83-88.
13. Christiansen C., Riis B.J., Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987, 1:1105-1108.
14. Pouillès J.M., Trémollière F., Ribot C. Variability of vertebral and femoral postmenopausal bone loss. Osteoporosis Int. 1996, 6:320-324.
15. Jones G., Nguyen T., Sambrook P., Kelly P.J., Eisman J.A. Progressive loss of bone in the femoral neck in elderly people, longitudinal findings from the Dubbo osteoporosis epidemiology study. Brit. Med. J. 1994, 309:691-695.
16. Prestwood K.M., Pilbeam C.C., Burleson J.A., Woodiel F.N., Delmas P.D., Deftos L.J., Raisz L.G. The short-term effects of conjugated estrogen on bone turnover in older women. J. Clin. Endocrinol. Metab. 1994, 79:366-371.
17. Heshmati H.M., Khosla S., Robins S.P., O'Fallon M., Melton L.J., Riggs B.L. Role of low levels of endogeneous estrogen in regulation of bone resorption in late postmenopausal women. J. Bone Miner. Res. 2002, 17:172-178.
18. Genant H.K., Cann C.E., Ettinger B., Gordon G.S. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann. Intern. Med. 1982, 97:699-705.
19. Slemenda C., Hui S.L., Longeope C., Johnston C.C. Sex steroids and bone mass: a study of changes about the time of menopause. J. Clin. Invest. 1987, 80:1261-1269.
20. Gordan G.S., Picchi J., Roof B.S. Antifracture efficacy of long term estrogens for osteoporosis. Trans. Assoc. Am. Physicians 1973, 86:326-332.
21. Ettinger B., Genant H.K., Cann C.E. Long term estrogen replacement therapy. 1. Metabolic effects. Am. J. Obstet. Gynecol. 1979, 133:525-536.
22. Hutchinson T.A., Polansky S.M., Feinstein A.R. Postmenopausal estrogens protect against fractures of hip and distal radius. Lancet 1979, 706-710.
23. Weiss N.S., Ure C.L., Ballard J.H., Williams A.R., Dailing J.R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N. Engl. J. Med. 1980, 303:1195-1198.
24. Johnson R.E., Specht E.E. The risk of hip fracture in postmenopausal females with and without estrogen drug exposure. Am. J. Public Health 1981, 71:138-144.
25. Kreiger N., Keysley J.L., Holford T.R., O'Connor T. An epidemiologic study of hip fracture in postmenopausal women. Am. J. Epidemiol. 1982, 116:141-148.
26. Williams A.R., Weiss N.S., Ure C.L., Ballard J., Dailing J. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet. Gynecol. 1982, 60:695-699.
27. Kanis J.A., Johnell O., Gulberg B., Allander E., Dilsen G., Gennari C., Lopes Vaz A.A., Lyritis G.P., Mazzuoli G., Miravet L. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Brit. Med. J. 1992, 305:1124-1128.
28. Chow J., Tobias J.H., Colston K.W., Chambers T.J. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J. Clin. Invest. 1992, 89:74-78.
29. Bain S.D., Bailey S.C., Celino D.L., Lantry M.M., Edwards M.W. High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomized mouse. J. Bone Miner. Res. 1993, 8:435-441.
30. Oursler M.J., Kassem M., Turner R., Riggs B.L., Spelsberg T.C. Regulation of bone cell function by gonadal steroids. Osteoporosis 1996, 237-260. Academic Press, San Diego, CA. R. Marcus, D. Feldman, J. Kelsey (Eds.).
31. Oursler M.J., Cortese C., Keeting P., Anderson M.A., Bonde S.K., Riggs B.L., Spelsberg T.C. Modulation of transforming growth factor-beta production in normal osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology 1991, 112:3313-3320.
32. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeltaon. Endocr. Rev. 2002, 23:279-302.
33. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endrocr. Rev. 2000, 21:115-137.
34. Pacifici R., Rifas L., McCracken R., Vered I., McMurtry C., Avioli L.V., Peck W.A. Ovarian steroid treatment blocks a postemenopausal increase in blood monocyte interleukine 1 release. Proc. Natl. Acad. Sci. USA 1989, 86:2398-2402.
35. Pacifici R., Vannice J.L., Rifas L., Kimble R.B. Monocytic secretion of interleukine-1 receptor antagonist in normal and osteoporotic women: Effects of menopause and estrogen/progesterone therapy. J. Clin. Endocrinol. Metab. 1993, 77:1135-1141.
36. McKane W.R., Khosla S., Peterson J.M., Egan K., Riggs B.L. Circulating levels of cytokines that modulate bone resorption. Effects of age and menopause in women. J. Bone Miner. Res. 1994, 9:1313-1318.
37. Cohen-Solal M.E., Craulet A.M., Denne M.A., Gueris D., Baylink D., de Vernejoul M.D. Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: Involvement of cytokines. J. Clin. Endocrinol. Metab. 1993, 77:1648-1653.
38. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999, 20:345-357.
39. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 2000, 15:2-12.
40. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK-ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003, 111:1221-1230.
41. Slemenda C., Longeope C., Peacock M., Hui S., Johnston C.C. Sex steroids, bone mass, and bone loss. A prospective study of pre,-peri and postmenopausal women. J. Clin. Invest. 1996, 97:14-21.
42. Cummings S.R., Browner W.S., Bauer D., Stone K., Ensrud K., Jamal S., Ettinger B. Endogenous hormones and the risk of hip and vertebral fractures among older women. N. Engl. J. Med. 1998, 339:733-738.
43. Chapurlat R.D., Gamero P., Bréart G., Meunier P.J., Delmas P.D. Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: The EPIDOS study. J. Bone Miner. Res. 2000, 15:1835-1841.
44. Gamero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J. Bone Miner. Res. 2000, 15:1526-1536.
45. Melton L.J., Crowson C.S., O'Fallon W.M., Wahner H.W., Riggs B.L. Relative contributions of bone density, bone turnover and clinical risk factors to long-term fracture predictions. J. Bone Miner. Res. 2003, 18:312-318.
46. Goderie-Pomp H.W., van der Klift M., de Ronde W., Hofman A., de Jong F.H., Plos H.A. Endogeneous sex hormones, sex-hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam study. J. Clin. Endocrinol. Metab. 2004, 898:3261-3269.
47. Tomkinson A., Reeve J., Shaw R.W., Noble B.S. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 1997, 82:3128-3135.
48. Dunstan C.R., Evans R.A., Hills E., Wong S.Y.P., Higgs R.J.E.D. Bone death in hip fracture in the elderly. Calcif. Tissue Int. 1990, 47:270-275.
49. Epstein S., Bryce G., Hinnan J.W., Miller O.N., Riggs B.L., Hui S.L., Johnson C.C. The influence of age on bone mineral regulating hormones. Bone 1986, 7:421-425.
50. Gamero P., Somay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 1996, 11:337-349.
51. Gamero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., Cormier C., Breart G., Meunier P.J., Delmas P.D. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective study. J. Bone Miner. Res. 1996, 11:1531-1538.
52. Mezquita-Raya P., Munoz-Torres M., De Dios Luna J., Luna V., Lopez-Rodriguez F., Tores-Vela E., Escobar-Jimenez F. Relation between vitamin D insufficiency, and bone metabolism in healthy postmenopausal women. J. Bone Miner. Res. 2001, 16:1408-1415.
53. Chapuy M.C., Arlot M.E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P.D., Meunier P.J. Vitamin D3 and calcium to prevent hip fractures in elderly women. N. Engl. J. Med. 1992, 327:1637-1642.
54. Passeri G., Pini G., Troiano L., Vescovini R., Sansoni P., Passeri M., Guerisi P., Delsignore R., Pedrazzoni M., Franceschi C. Low vitamin D status, high bone turnover, and bone fractures in centenarians. J. Clin. Endocrinol. Metab. 2003, 88:5109-5115.
55. Hammerman M.R. Insuline-like growth factors and aging. Endocrinol. Metab. Clin. North Am. 1987, 16:995-1008.
56. Nicolas V., Prewett V., Bettica P., Mohan P., Finfleman R.D., Baylink D.J., Farley J.T. Age-related decreases in IGF-1 and transforming growth factor beta in femoral cortical bone from both men and women: implications for loss in aging. J. Clin. Endocrinol. Metab. 1994, 78:1001-1016.
57. Sugimoto T., Nishiyama K., Kuribayashi F., Chihara K. Serum levels of insuline-like growth factor (IGF) I and IGF-Biding protein (IGFBP)-2 and IGFBP-3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 1997, 12:1272-1279.
58. Ueland T., Brixen K., Mosekilde L., Fyvbjerg A., Bollerslev J. Age-related changes in cortical bone content of insulin-like growth factor binding (IGFBP)-3, IGFBP-5, osteoprotegerin and calcium in postmenopausal osteoporosis: a crossectional study. J. Clin. Endocrinol. Metab. 2003, 88:1014-1018.
59. Silha J.V., Mishra S., Rosen C.J., Beamer W.G., Turner R.T., Powell D.R., Murphy L.J. Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J. Bone Miner. Res. 2003, 18:1834-1841.
60. Thomas T., Gori F., Khosla S., Jensen M.D., Burguera B., Riggs B.L. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiati on to adipocytes. Endocrinology 1999, 140:1630-1638.
61. Holloway W.R., Collier F.M., Aitken C.J., Myers D.E., Hodge J.M., Malakellis M., Gough T.J., Collier G.R., Nicholson G.C. Leptin inhibits osteoclast generation. J. Bone Miner. Res. 2002, 17:200-209.
62. Steppan C.M., Crawford D.T., Chidsey-Frink K.L., Ke H., Swick A.G. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul. Pept. 2000, 92:73-78.
63. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., Shen J., Vinson C., Rueger J.M., Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000, 100:197-207.
64. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Amstrong D., Ducy P., Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
65. Burguera B., Hofbauer L.C., Thomas T., Gori F., Evans G.L., Khosla S., Riggs B.L., Turner R.T. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 2001, 142:3546-3553.
66. Sheidt-Nave C., Bismar H., Leidig-Bruckner G., Woitge H., Seibel M.J., Zeigler R., Pfeilschifter J. Serum interleukin 8 is a major predictor of bone loss in women specific to the first decade. J. Clin. Endocrinol. Metab. 2001, 86:2032-2042.
67. Abrahamsen B., Bonnevie-Nielsen V., Ebbesen E.N., Gram J., Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses soluble interleukin-6 receptor and increases interleukin-1 receptor antagonist: the Danish osteoporosis prevention study. J. Bone Miner. Res. 2000, 15:1545-1554.
68. Garnero P., Sornay-Rendu E., Delmas P.D. Low levels of serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000, 355:898-899.
69. Boonen S., Mohan S., Dequecker J., Aerssens J., Vanderschueren D., Verbeke G., Broos P., Bouillon R., Baylink D.J. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF-binding protein (BP)-3 and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J. Bone Miner. Res. 1999, 14:2140-2158.
70. Thomas T., Burguera B., Melton L.J., Atkinson E.J., O'Fallon W.M., Riggs B.L., Khosla S. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001, 29:114-120.
71. Yamauchi M., Sugimoto T., Yamaguchi T., Nakaoka D., Kanzawa M.aiYano^S., Ozuru R., Sugishita T., Chihara K. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin. Endocrinol. (Oxf) 2001, 55:341-347.
72. Pasco J.A., Henry M.J., Kotowicz M.A., Collier G.R., Ball M.J., Ugoni A.M., Nicholson G.C. Serum leptin levels are associated with bone mass in nonobese women. J. Clin. Endocrinol. Metab. 2001, 86:1884-1887.
73. Blain H., Vuillemin A., Guillemin F., Durant R., Hanesse B., de Talance N., Doucet B., Jeandel C. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 2002, 87:1030-1035.
74. Martini G., Valenti R., Giovani S., Franci S., Campagna S., Nuti R. Influence of insulin-like growth factor and leptin on bone mass in healthy postmenopausal women. Bone 2001, 28:113-117.
75. Ruhl C.E., Everhart J.E. Relationship of serum leptin concentration with bone mineral density in the United States population. J. Bone Miner. Res. 2002, 17:1896-1903.
76. Roux C., Arabi A., Porcher R., Gamero P. Serum leptin as a determinant of bone resorption in healthy postmenopausal women. Bone 2003, 33:847-852.
77. Kontogianni M.D., Dafni U.G., Routsias J.G., Skopouli F.N. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J. Bone Miner. Res. 2004, 19:546-551.
78. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal with osteoporosis. J. Bone Miner. Res. 1999, 14:518-527.
79. Rogers A., Saleh S., Hannon R.A., Greenfield D., Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone tumover and bone density in postmen opausal women. J. Clin. Endocrinol. Metab. 2002, 87:4470-4475.
80. Fahrleitner A., Prenner G., Leb G., Tscheliessnigg K.H., Piswanger-Solkner C., Obermayer-Pietsch B., Portugaller H.R., Berghold A., Dobnig H. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003, 32:96-106.
81. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels, diabetes, stroke, bone density, fractures and mortality in elderly women. J. Clin. Endocrinol. Metab. 2001, 86:631-637.
82. Khosla S., Arrighi H.M., Melton L.J., Atkinson E.J., O'Fallon W.M., Dunstan C., Riggs B.L. Correlates of osteoprotegerin levels in women and men. Osteoporos. Int. 2002, 13:394-399.
83. Schett G., Kiechl S., Redlich K., Oberhollenzer F., Weger S., Egger G., Mayr A., Jocher J., Xu Q., Pierschmann P., Teitelbaum S., Smolen J., Willeit J. Soluble RANKL and the risk of non traumatic fracture. JAMA 2004, 291:1108-1113.
84. Szulc P., Hofbauer L.C., Heufelder A.E., Rothe S., Delmas P.D. Osteoprotegerin serum levels in men: correlation with age, estrogen and testosterone status. J. Clin. Endocrinol. Metab. 2001, 86:3162-3165.
85. Tomoyasu A., Masaaki G., Fujisi N., Mochizuki S., Yasuda H., Morinaga T., et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem. Biophys. Res. Commun. 1998, 245:382-387.
86. Anonymous Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am. J. Med. 1993, 94:646-650.
87. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Brit. Med. J. 1996, 312:1254-1259.
88. Miller P.D., Siris E.S., Barret-Connor E., Faulkner K.G., Wehren L.E., Abbott T.A., Chen Y-T., Berger M.L., Santora A.C., Sherwood L.M. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: Evidence from the National Osteoporosis Risk Assessment. J. Bone Miner. Res. 2002, 17:2222-2230.
89. Broe K.D., Hannan M.T., Kiely D.K., Cali C.M., Cupples L.A., Kiel D.P. Predicting fractures using bone mineral density: a prospective study of long-term care residents. Osteoporos. Int. 2000, 11:765-771.
90. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., Vogt T.M. Risk factors for hip fracture in white women. N. Engl. J. Med. 1995, 332:767-773.
91. Bouxsein M.L., Palermo L., Yeung C., Black D.M. Digital X-ray radiogrammetry predicts hip, wrist and vertebral fracture risks in elderly women. A prospective analysis from the study of osteoporotic fractures. Osteoporos. Int. 2002, 13:358-365.
92. Schott A.M., Cormier C., Hans D., Favier F., Hausherr E., Dargent-Molina P., Delmas P.D., Ribot C., Sebert J.L., Breart G., Meunier P.J. How hip and whole body bone mineral density predict hip fracture in elderly women: the EPIDOS prospective study. Osteoporos. Int. 1998, 8:247-254.
93. Duboeuf F., Hans D., Schott A.M., Kolzki P.O., Favier F., Marcelli C., Meunier P.J., Delmas P.D. Different morphometric and densitometric parameters predict cervical and trochanteric hip fracture: the EPIDOS study. J. Bone Miner. Res. 1997, 12:1895-1902.
94. Bolotin H.H., Sievänen H., Grashuis J.L., Kuiper J.W., Järvinen T.L.N. Inaccuracies inherent in patients-specific dual energy X-ray absorptiometry bone mineral density measurements: Comprehensive phantom-based evaluation. J. Bone Miner. Res. 2001, 16:417-426.
95. Bolotin H.H. Inaccuracies inherent in dual-energy X-ray absorptiometry in vivo bone mineral densitometry may flaw osteopenic/osteoporotic interpretations and mislead assessment of antiresorptive effectiveness. Bone 2001, 28:548-555.
96. Bolotin H.H., Sievänen H., Grashuis J.L. Patient-specific DXA bone mineral density inaccuracies: Quantitative effects of nonuni-form extraosseous fat distributions. J. Bone Miner. Res. 2003, 18:1020-1027.
97. Muller M.E., Webber C.E., Bouxtein M.L. Predicting the failure load of the distal radius. Osteoporos. Int. 2003, 14:345-352.
98. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 1996, 11:337-349.
99. Stepan J.J. Prediction of bone loss in postmenopausal women. Osteoporos. Int. Suppl. 2000, 6:S45-S54.
100. Johansen J.S., Riis B.J., Delmas P.D., Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and effect of estrogen treatment in postmenopausal women. Eur. J. Clin. Invest. 1988, 18:191-195.
101. Garnero P., Somay Rendu E., Duboeuf F., Delmas P.D. Markers of bone turnover predict postmenopausal bone loss over 4 years: The OFELY study. J. Bone Miner. Res. 1999, 14:399-406.
102. Bauer D.C., Sklarin P.M., Stone K.T., Black D.M., Nevitt M.C., Ensrud K., Amaud C.D., Genant H.K., Gamero P., Delmas P.D., Lawaetz H., Cummings S.R. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures. J. Bone Miner. Res. 1999, 8:1404-1410.
103. Ross P.D., Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J. Bone Miner. Res. 1998, 13:297-302.
104. Hansen M.A., Kirsten O., Riss B.J., Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. Brit. Med. J. 1991, 303:961-964.
105. Stone K.L., Seeley D.G., Lui L.Y., Cauley J.A., Ensrud K., Browner W.S., Nevitt M.C., Cummings S.R. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J. Bone. Miner. Res. 2003, 18(11):1947-1954.
106. Schuit S.C.E., van der Klift M., Weel A.E.A.M., de Laet C.E.D.H., Buerger H., Seeman E., Hofman A., Uitterlinden A.G., van Leeuwen J.P.T.M., Pols H.A.P. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004, 31:195-202.
107. Riis S.B.J., Hansen A.M., Jensen K., Overgaard K., Christiansen C. Low bone mass and fast rate of bone loss at menopause-equal risk factors for future fracture. A 15 year follow-up study. Bone 1996, 19:9-12.
108. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos. Int. 2000, Suppl 6:S55-S65.
109. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., Cormier C., Breart G., Meunier P.J., Delmas P.D. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J. Bone Miner. Res. 1996, 11:1531-1538.
110. Gerdhem P., Ivaska K.K., Alatalo S.L., Hallen J.M., Hellman J., Isaksson A., Pettersson K., Väänänen H.K., Akesson K., Obrandt K.J. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J. Bone Miner. Res. 2004, 19:386-393.
111. Ross P.D., Kress B.C., Parson R.E., Wasnich R.D., Arnour K.A., Mizrahi I.A. Serum bone alkaline phosphatse and calcaneus bone density predict fractures: A prospective study. Osteoporos. Int. 2000, 11:76-82.
112. Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., Delmas P.D. Markers of bone turnover and history of prior fractures as predictors of long term fracture risk in postmen opausal women without osteoporosis: the OFELY Study. J. Bone Miner. Res. 2003, 18:S66. Supp 2.
113. van Daele P.L.A., Seibel M.J., Burger H., Hofman A., Grobbee D.E., van Leeuwen J.P.T.M., Birkenhager J.C., Pols H.A.P. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study. Brit. Med. J. 1996, 312:482-483.
114. Qvist P., Christgau S., Pedersen B.J., Schlemmer A., Christiansen C. Circadian variation in the serum C-terminal telopeptide of type I collagen (Serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting. Bone 2002, 31:57-61.
115. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002, 30:307-313.
116. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., Byrjalsen I., Krarup T., Holst J.J., Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J. Bone Miner. Res. 2003, 18:2180-2189.
117. Chapurlat R.D., Gamero P., Breart G., Meunier P.J., Delmas P.D. Serum type 1 collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000, 27:283-286.
118. Bauer D.C., Black D.M., Ensrud K., Qvist P., Williams E. Serum markers of bone turnover and fractures of the hip and spine: A prospective study. J. Bone Miner. Res. 1999, 14(Suppl 1):S147.
119. Batge B., Deibold J., Stein H., Bodo M., Muller P.K. Compositional analysis of the collagenous bone matrix. A study on adult normal and osteopenic bone tissue. Eur. J. Clin. Invest. 1992, 22:805-812.
120. Kowitz J., Knippel M., Schuhr T., Mach J. Alteration in the extent of collagen 1 hydroxylation, isolated from femoral heads of women with a femoral neck fracture caused by osteoporosis. Calcif. Tissue Int. 1992, 60:501-505.
121. Bailey A.J., Wotton S.F., Sims T.J., Thompson P.W. Post-translational modifications in the collagen of human osteoporotic femoral head. Biochem. Biophys. Res. Commun. 1992, 185:801-805.
122. Oxlund H., Moselkilde L., Ortoft G. Reduced concentration of collagen reducible cross-links in human trabecular bone with respect to age and osteoporosis. Bone 1996, 19:479-484.
123. Banse X., Sims T.J., Bailey A.J. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J. Bone Miner. Res. 2002, 17:1621-1628.
124. Wang X., Shen X., Li X., Agrawal C.M. Age-related changes in collagen network and toughness of bone. Bone 2002, 31:1-7.
125. Cloos P.A.C., Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem. J. 2000, 345:473-480.
126. Gamero P., Fledelius C., Gineyts E., Serre C.M., Vignot E., Delmas P.D. Decreased ? isomerisation of C-telopeptides of type I collagen in Paget's disease of bone. J. Bone. Miner. Res. 1997, 12:1407-1415.
127. Gamero P., Cloos P., Somay-Rendu E., Qvist P., Delmas P.D. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study. J. Bone Moner. Res. 2002, 17:826-833.
128. Garnero P., Qvist P., Munoz M., Sonay-Rendu E., Christiansen C., Delmas P.D. Type I collagen C-telopeptide isomerization predicts the long-term risk of non-vertebral fracture in postmenopausal women, independently of bone mineral density and bone turnover: a non invasive index of bone collagen quality. J. Bone Miner. Res. 2004, 19(Suppl 1):S19.
129. Garnero P., Borel O., Gineyts E., Duboeuf F., Christiansen C., Delmas P.D. The degree of postrranslational modifications of collagen is an important deteminant of the toughness of cortical bone. J. Bone Miner. Res. 2004, 19(Suppl 1):S220.
130. Kang A.H., Trelstad R.L. A collagen defect in homocystinuria. J. Clin. Invest. 1971, 52:2571-2578.
131. Lubec B., Fang-Kircher S., Lubec T., Blom H.J., Boers G.H. Evidence for McKusick's hypotheis of deficient collagen cross-linking in patients with homocystinuria. Biochem. Bipohys. Acta. 1996, 1315:159-162.
132. McLean R.R., Jacques P.F., Selhub J., Tucker K.L., Samelson E.J., Broe K.E., Hannan M.T., Cupples L.A., Kiel D.P. Homocysteine as a predictive factor for hip fracture in older persons. N. Engl. J. Med. 2004, 350:2042-2049.
133. van Meurs J.B.J., Dhonukshe-Rutten R.A.M., Pluijn S.M.F., et al. Homocysteine levels and the risk of osteoporotic fracture. N. Engl. J. Med. 2004, 350:2033-2041.
134. Raisz L.G. Homocysteine and osteoporotic fracture Culprit or bystander?. N Engl. J. Med. 2004, 350:2089-2090.
135. Shiraki M., Shiraki Y., Aoki C., Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar spine bone mineral density in osteoporosis. J. Bone Miner. Res. 2000, 15:515-521.
136. Szulc P., Chapuy M.C., Meunier P.J., Delmas P.D. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 1993, 91:1769-1774.
137. Vergnaud P., Garnero P., Meunier P.J., Breart G., Kamilhagi K., Delmas P.D. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J. Clin. Endocrinol. Metab. 1997, 82:719-724.
138. Luukinen H., Kakonen S.M., Pettersson K., Koski K., Laippala P., Lovgren T., Kivela S.L., Vaananen H.K. Strongprediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J. Bone Miner. Res. 2000, 15:2473-2478.
139. Liu G., Peakcock M. Age-related changes in serum undercarboxy lated osteocalcin and its relationships with bone density, bone quality, and hip fracture. Calcif. Tissue. Int. 1998, 62:286-289.
140. Sugiyama T., Kawai S. Carboxylation of osteocalcin may be related to bone quality: a possible mechanism of bone fracture prevention by vitamin K. J. Bone Miner. Metab. 2001, 19:146-149.
141. Garnero P., Dargent-Molina P., Hans D., Schott A.M., Bréart G., Meunier P.J., Delmas P.D. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos. Int. 1998, 8:563-569.
142. Johnell O., Oden A., De Laet C., Gamero P., Delmas P.D., Kanis J.A. Biochemical markers and the assessment of fracture probability. Osteoporos. Int. 2002, 13:523-526.
143. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., Adami S., Fogelman I., Diamond T., Eastell R., Meunier P.J., Reginster J.Y. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 2001, 344:333-340.
144. Kanis J.A., Johnell O., Black D.M., Downs R.W., Sarkar S., Fuerst T., Secrest R.J., Pavo I. Effect of raloxifène on the risk of new vertebral fracture in post-menopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 2003, 33:293-300.
145. Black D.M., Thompson D., Quandt S., Palermo L., Ensrud K., Johnell O. Alendronate reduces the risk of vertebral fracture in women with BMDT-scores above-2.5; results from the Fracture Intervention Trial (FIT). Osteoporos. Int. 2002, 13(Suppl 1):S27.
146. Bauer D.C., Gamero P., Hochberg M.C., Santora A., Delmas P.D., Ewing S.K., Black D.M. Pre-treatment bone tumover and fracture efficacy of alendronate: the Fracture Intervention Trial. J. Bone Miner. Res. 2003, 18(Suppl 2):S55.